Jennison Associates LLC lowered its stake in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 33.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 70,117 shares of the medical instruments supplier’s stock after selling 35,395 shares during the quarter. Jennison Associates LLC’s holdings in Insulet were worth $14,713,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in PODD. Larson Financial Group LLC grew its stake in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new position in Insulet during the 4th quarter worth approximately $28,000. DV Equities LLC bought a new position in Insulet in the fourth quarter worth approximately $28,000. Finally, MV Capital Management Inc. bought a new position in Insulet in the fourth quarter worth approximately $29,000.
Key Headlines Impacting Insulet
Here are the key news stories impacting Insulet this week:
- Positive Sentiment: No clearly positive company-specific catalysts were identified in the latest news flow.
- Neutral Sentiment: Multiple law firms, including Pomerantz, Schall, Robbins, Rosen, Faruqi, Gross, Bronstein, Levi & Korsinsky, and BFA Law, issued class-action filings or investor reminders related to PODD shares purchased between February 2025 and May 2026, keeping the issue in the spotlight. Pomerantz Law Firm article
- Neutral Sentiment: The litigation references an August 31, 2026 lead-plaintiff deadline, suggesting the legal process is still in an early procedural stage rather than reflecting a final outcome. SueWallSt deadline reminder article
- Negative Sentiment: The core allegation is that confidence in Insulet’s manufacturing story “collapsed” after two Omnipod recalls exposed quality failures, which could raise concerns about future product reliability, regulatory scrutiny, and potential financial liabilities. Bleichmar Fonti & Auld lawsuit notice article
Insulet Stock Performance
Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the previous year, the company earned $1.02 earnings per share. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts forecast that Insulet Corporation will post 6.45 EPS for the current fiscal year.
Insider Buying and Selling at Insulet
In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is owned by insiders.
Analysts Set New Price Targets
Several equities research analysts have recently commented on PODD shares. Benchmark restated a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Piper Sandler cut their target price on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. JPMorgan Chase & Co. reduced their price target on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Stifel Nicolaus decreased their price target on shares of Insulet from $250.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Finally, Oppenheimer lowered their price objective on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $235.25.
Read Our Latest Report on PODD
Insulet Company Profile
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Articles
- Five stocks we like better than Insulet
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
